Advances in post-translational modifications of proteins and cancer immunotherapy
Regul Pept 2011;169:43-48
The FDA shortage designation for semaglutide and tirzepatide - which originally provided the regulatory basis for much of the compounded GLP-1 market - has been resolved, and the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after stating it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances
As one might expect, people who began using CGM more quickly after starting a GLP-1 saw the greatest reduction in A1C
Expanding Access to No-Cut Facelift Procedures in Austin The addition of no-cut facelift Austin options to the practice's service offerings gives patients an alternative path to facial rejuvenation that avoids incisions, general anesthesia, and extended downtime
(547) revealed a crucial clinical application of curcumin in mitigating cerebral ischemia-reperfusion (I/R) injury, a significant cause of neuronal damage and neurological dysfunction
